Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$6.27 - $7.7 $1.54 Million - $1.89 Million
-245,900 Reduced 61.75%
152,300 $959,000
Q1 2024

May 07, 2024

BUY
$5.47 - $11.38 $2.11 Million - $4.4 Million
386,300 Added 3246.22%
398,200 $2.66 Million
Q4 2023

Feb 14, 2024

SELL
$7.71 - $11.56 $126,444 - $189,584
-16,400 Reduced 57.95%
11,900 $137,000
Q3 2023

Nov 14, 2023

SELL
$8.91 - $10.91 $1.5 Million - $1.83 Million
-168,100 Reduced 85.59%
28,300 $258,000
Q2 2023

Aug 11, 2023

SELL
$7.14 - $9.29 $127,092 - $165,361
-17,800 Reduced 8.31%
196,400 $1.8 Million
Q1 2023

May 16, 2023

BUY
$6.65 - $10.69 $1.22 Million - $1.96 Million
183,400 Added 595.45%
214,200 $1.58 Million
Q4 2022

Feb 14, 2023

SELL
$5.96 - $8.53 $225,884 - $323,287
-37,900 Reduced 55.17%
30,800 $261,000
Q3 2022

Nov 14, 2022

BUY
$5.95 - $14.3 $243,355 - $584,870
40,900 Added 147.12%
68,700 $423,000
Q2 2022

Aug 15, 2022

SELL
$10.6 - $13.28 $755,780 - $946,864
-71,300 Reduced 71.95%
27,800 $330,000
Q1 2022

May 16, 2022

BUY
$10.37 - $12.73 $841,006 - $1.03 Million
81,100 Added 450.56%
99,100 $1.16 Million
Q4 2021

Feb 14, 2022

SELL
$10.21 - $15.27 $88,827 - $132,849
-8,700 Reduced 32.58%
18,000 $202,000
Q1 2021

May 17, 2021

SELL
$15.15 - $19.78 $53,025 - $69,230
-3,500 Reduced 11.59%
26,700 $462,000
Q4 2020

Feb 16, 2021

BUY
$16.86 - $19.67 $291,678 - $340,291
17,300 Added 134.11%
30,200 $557,000
Q2 2020

Aug 14, 2020

SELL
$18.24 - $21.45 $1.14 Million - $1.34 Million
-62,600 Reduced 82.91%
12,900 $235,000
Q1 2020

May 15, 2020

SELL
$16.28 - $25.63 $833,536 - $1.31 Million
-51,200 Reduced 40.41%
75,500 $1.52 Million
Q4 2019

Feb 14, 2020

BUY
$19.57 - $23.52 $1.16 Million - $1.4 Million
59,500 Added 88.54%
126,700 $2.95 Million
Q3 2019

Nov 14, 2019

BUY
$19.85 - $22.76 $1.33 Million - $1.53 Million
67,200 New
67,200 $1.35 Million

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.99B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.